Abstract Objective To investigate the clinical and genetic features of two families with late-onset glutaric aciduria type Ⅱ caused by ETFDH mutations. Methods Target gene sequence capture and next generation sequencing were used for sequencing of suspected patients and their family members. The patients' clinical features were retrospectively analyzed and literature review was performed. Results The probands of the two families had a clinical onset at the ages of 10 years and 5.5 years respectively, with the clinical manifestations of muscle weakness and muscle pain. Laboratory examinations revealed significant increases in the serum levels of creatine kinase, creatine kinase-MB, and lactate dehydrogenase. Tandem mass spectrometry showed increases in various types of acylcarnitines. The analysis of urine organic acids showed an increase in glutaric acid. Electromyography showed myogenic damage in both patients. Gene detection showed two novel mutations in the ETFDH gene (c.1331T > C from the mother and c.824C > T from the father) in patient 1, and the patient's younger brother carried the c.1331T > C mutation but had a normal phenotype. In patient 2, there was a novel mutation (c.177insT from the father) and a known mutation (c.1474T > C from the mother) in the ETFDH gene. Several family members carried such mutations. Both patients were diagnosed with glutaric aciduria type Ⅱ. Their symptoms were improved after high-dose vitamin B2 treatment. Conclusions For patients with unexplained muscle weakness and pain, serum creatine kinase, acylcarnitines, and urinary organic acids should be measured, and the possibility of glutaric aciduria type Ⅱ should be considered. Genetic detection is helpful to make a confirmed diagnosis.
CHENG Yan-Yang,TANG Yue,LIU Ao-Jie et al. Clinical features and ETFDH mutations of children with late-onset glutaric aciduria type Ⅱ:a report of two cases[J]. CJCP, 2017, 19(9): 975-978.
CHENG Yan-Yang,TANG Yue,LIU Ao-Jie et al. Clinical features and ETFDH mutations of children with late-onset glutaric aciduria type Ⅱ:a report of two cases[J]. CJCP, 2017, 19(9): 975-978.
Zhu M, Zhu X, Qi X, et al. Riboflavin-responsive multiple Acyl-CoA dehydrogenation deficiency in 13 cases, and a literature review in mainland Chinese patients[J]. J Hum Genet, 2014, 59(5):256-261.
Henriques BJ, Rodrigues JV, Olsen RK, et al. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency:a molecular rationale for the effects of riboflavin supplementation[J]. J Biol Chem, 2009, 284(7):4222-4229.
[4]
Przyrembel H, Wendel U, Becker K, et al. Glutaric aciduria type Ⅱ:report on a previously undescribed metabolic disorder[J]. Clin Chim Acta, 1976, 66(2):227-239.
Yamada K, Kobayashi H, Bo R, et al. Clinical, biochemical and molecular investigation of adult-onset glutaric acidemia type Ⅱ:Characteristics in comparison with pediatric cases[J]. Brain Dev, 2016, 38(3):293-301.
[7]
Fu HX, Liu XY, Wang ZQ, et al. Significant clinical heterogeneity with similar ETFDH genotype in three Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency[J]. Neurol Sci, 2016, 37(7):1099-1105.
[8]
Xi J, Wen B, Lin J, et al. Clinical features and ETFDH mutation spectrum in a cohort of 90 Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency[J]. J Inherit Metab Dis, 2014, 37(3):399-404.
[9]
Lund AM, Skovby F, Vestergaard H, et al. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders[J]. J Inherit Metab Dis, 2010, 33(5):495-500.
[10]
Wen B, Dai T, Li W, et al. Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations[J]. J Neurol Neurosurg Psychiatry, 2010, 81(2):231-236.
[11]
Olsen RK, Andresen BS, Christensen E, et al. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency[J]. Hum Mutat, 2003, 22(1):12-23.
